Program for reallocation of influenza vaccine
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields



Publication Date Range:


Document Data


Document Type:






Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page


Program for reallocation of influenza vaccine

Filetype[PDF-577.23 KB]

  • English

  • Details:

    • Journal Article:
    • Description:
      Wednesday, November 24, 2004, 16:51 EST (4:51 PM EST)


      Since Chiron Corporation's October announcement, that the company could not provide vaccine for distribution in the United States for the 2004-2005 influenza season, CDC has worked closely with vaccine manufacturer Aventis Pasteur and State Health Officials to distribute available vaccine to the most vulnerable individuals and those who care for them.

      CDC appreciates the tremendous efforts from states and urban areas to distribute and administer influenza vaccine to those most in need. CDC discourages use of vaccine for individuals not considered high-priority until we have met the demand for the priority population in every state. CDC will reallocate vaccine from states or urban areas that report having more than enough vaccine to serve their targeted populations to the remaining states or urban areas. High priority populations identified by the Advisory Committee for Immunization Practices (ACIP) for vaccination with inactivated influenza vaccine are identified at

      By early October, Aventis Pasteur had already shipped 33 million of its expected total 58 million vaccine doses. Together, CDC and Aventis Pasteur decided to fill orders placed with Aventis Pasteur and Chiron distributors that were easily identifiable as intended for providers serving substantial numbers of high risk patients.

    • Series:
    • Document Type:
    • Place as Subject:
    • Location:
    • Main Document Checksum:
    • File Type:

    Supporting Files

    • No Additional Files

    More +

    You May Also Like

    Checkout today's featured content at